Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Clinical Evaluation GL for Anti-RA, Other Drugs to Be Prepared by PFSB: SJP Meeting
March 15, 2004
- Draft GL for Drug Testing Organizations Presented
March 15, 2004
- REGULATORY NEWS IN BRIEF
March 15, 2004
- Korosho to Promote Prevention of the Need for Nursing Care
March 15, 2004
- Generic Drug Use Increasing Steadily at Pref. Hospitals: PJ Survey
March 15, 2004
- Pharma Sales to Fall Short of Forecast in FY2003: Ajinomoto
March 8, 2004
- Daiichi to Establish R&D Subsidiary in the US Aimed at FDA Applications
March 8, 2004
- The Economist Conferences
March 8, 2004
- Taiyo to Expand "Total Contract Manufacturing" Business
March 8, 2004
- BUSINESS NEWS IN BRIEF
March 8, 2004
- PFSB to Revise GL on Information Disclosure
March 8, 2004
- REGULATORY NEWS IN BRIEF
March 8, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 8, 2004
- INF b-1b Effective against Multiple Sclerosis: Nihon Schering Seminar
March 8, 2004
- Annual Business Results
March 8, 2004
- 1st 3 Qtrs Business Results
March 8, 2004
- Lower Cholesterol Reduces Vascular Disease Risk: Banyu Symposium
March 8, 2004
- Novo Nordisk to Introduce New MR Training System in April
March 8, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 8, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 8, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…